Key result
A cocktail of etesevimab and JS026 exhibited synergistic neutralization against wild-type SARS-CoV-2 and variants of concern in vitro and significantly reduced viral titers in hACE2 transgenic mice.
Why the study?
Residual changes on the SARS-CoV-2 spike protein can decrease neutralizing antibody efficiency, making therapeutic antibody cocktails a potential countermeasure.
Does a cocktail of etesevimab and JS026 neutralize SARS-CoV-2 and reduce viral load in hACE2 transgenic mice?
Does a cocktail of etesevimab and JS026 neutralize SARS-CoV-2 and reduce viral load in hACE2 transgenic mice?
A cocktail of etesevimab and JS026 provides synergistic neutralization against SARS-CoV-2 and its variants, offering a potential therapeutic strategy for COVID-19.
The neutralizing antibody is a potential therapeutic for the ongoing COVID-19 pandemic. As an antiviral agent, numerous mAbs recognize the epitopes that overlap with ACE2-binding sites in the SARS-CoV-2-RBD. Some studies have shown that residual changes on the spike protein can significantly decrease the efficiency of neutralizing antibodies. To address this issue, a therapeutic cocktail could be an effective countermeasure. In the present study, we isolated a fully human neutralizing antibody, JS026, from a convalescent patient. The comparative analysis revealed that JS026 binding to SARS-CoV-2-RBD mainly located between epitopes for class 2 and class 3 mAbs as opposed to that of class 1 (etesevimab) antibodies. A cocktail of etesevimab and JS026 increased neutralizing efficacy against both wild-type SARS-CoV-2 and the recent emergence of Alpha, Beta, Gamma, and Delta variants. JS026 and the cocktail reduced virus titers in the infected lungs of hACE2 transgenic mice and relieved pathological changes. These findings would benefit antibody-based therapeutic countermeasures in the treatment of COVID-19.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2022) studied SARS-CoV-2 infection. Etesevimab and JS026 cocktail vs. Vehicle control / single antibody was evaluated on Neutralization activity and viral titer reduction. A cocktail of etesevimab and JS026 exhibited synergistic neutralization against wild-type SARS-CoV-2 and variants of concern in vitro and significantly reduced viral titers in hACE2 transgenic mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: